newsfilter
← Latest News
GlobeNewswire·

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

  • Recursion has secured FDA alignment on the design for its registrational Phase 3 trial of REC-4881, an AI-discovered oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP), a disease with no approved pharmacologic therapies.
  • The trial's primary endpoint is event-free survival, featuring a novel component where the excision of adenomas ≥10 mm in the upper or lower gastrointestinal tract counts as a clinically meaningful event.
  • Secondary endpoints will include modified Spigelman stage progression & total polyp burden.
  • The randomized, double-blind, placebo-controlled study is expected to enroll approximately 200 adults aged 18+ with FAP who have undergone colectomy or proctocolectomy.
  • REC-4881 is among the first AI-enabled programs to advance a Phase 3 design for a disease lacking approved treatments, identified via Recursion's unbiased phenotypic screening.
  • The trial is on track to begin in the second half of 2027, with dosing to be determined based on data from the ongoing TUPELO Phase 1b/2 trial.
  • Updated TUPELO data showed a 47% median reduction in total polyp burden after 12 weeks of treatment, with no new safety signals observed.
  • FAP affects over 50,000 patients in the US & EU5, where colectomy does not eliminate the risk of polyp formation or cancer in the remaining gastrointestinal tract.
Company
Recursion Pharmaceuticals
Keywords
Nasdaq:RXRX, Recursion Pharmaceuticals, rxrx, biotech, techbio